Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Feb 28;59(4):1577–1590. doi: 10.1002/hep.26898

Figure 7. DEN administration activates HSC through increased EGFR signaling which is inhibited by erlotinib.

Figure 7

Male Wistar rats received PBS or DEN for 18 weeks. DEN-injured rats received erlotinib (0.5 or 2 mg/kg) during weeks 13 – 18. (A) Representative photomicrographs of liver sections from PBS or DEN rats that were stained for α-SMA (Magnification 100X). (B) Liver sections from rats that received PBS as well as DEN-injured rats treated with vehicle (Control) or Erlotinib 2 mg/kg were costained for p-EGFR (Y1068) and either GFAP, desmin or α-SMA (Magnification 400X). (C) Representative photomicrographs of liver sections from DEN rats treated with erlotinib that were stained for α-SMA (Magnification 40X). Representative western blot analysis of (D) primary rat HSCs grown in culture for either 4 or 14 days and (E) primary rat HSCs treated with 100 ng/ml EGF in the absence of presence of 2 µM erlotinib for 30 minutes.